Scientists at the Hudson Institute of Medical Research have made a groundbreaking discovery that could significantly impact our understanding and treatment of stomach cancer. They've found that the bacterium Helicobacter pylori, a major cause of peptic ulcers and stomach cancer, uses extracellular vesicles (EVs) to deliver a key disease-causing protein, Tipα, directly into human cells.
This is a major breakthrough because it reveals a new mechanism by which H. pylori causes disease. Tipα, previously known to scientists but with conflicting results about its role, is now shown to be packaged inside EVs, which act as microscopic "delivery pods" transporting bacterial molecules into human cells. This discovery provides crucial insights into how H. pylori modulates chronic inflammation and promotes cancer, potentially opening new diagnostic and therapeutic pathways.
The study, led by Jack Emery and Professor Richard Ferrero, found that Tipα is primarily released from the bacteria in EVs, contrary to previous assumptions. These EVs then deliver Tipα directly into the nucleus of human stomach cells, where it binds to host DNA. Interestingly, this delivery method actually suppresses inflammation, reducing the production of TNF and IL-8, which may help H. pylori persist in the stomach for decades. This chronic, low-grade inflammatory environment is believed to eventually lead to stomach cancer.
The implications of this discovery are far-reaching. It suggests that Tipα-containing EVs may be detectable in blood, saliva, or gastric fluid, offering a potential early warning sign of infection or cancer risk. This could lead to new biomarkers for early detection. Additionally, understanding how Tipα is packaged and delivered may help researchers design vaccines that block this process, and targeting EV-mediated delivery could weaken the bacterium's ability to persist, leading to new therapeutic strategies.
The research was a global collaboration, led from Melbourne, involving collaborators from UNSW Sydney and international partners in Thailand, Brazil, the United States, and France. The team is now investigating how Tipα interacts with human DNA, whether Tipα-containing EVs can be detected in patient samples, and how EV-mediated delivery influences long-term cancer risk. The ultimate goal is to develop better tools to identify those most at risk and prevent cancer before it develops.
This discovery is a major step toward preventing stomach cancer, which ranks fifth globally for both incidence and mortality. By revealing a new mechanism by which H. pylori causes disease, the Hudson researchers have opened the door to a new generation of diagnostics and treatments, making stomach cancer far more preventable.
